Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study

References

• Cloutier MM, Baptist AP, Blake KV, Brooks EG, Bryant-Stephens T, DiMango E, Dixon AE, Elward KS, Hartert T, Krishnan JA, et al. 2020 Focused updates to the asthma management guidelines: a Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi:10.1016/j.jaci.2020.10.003.
   PubMed Web of Science ®Google Scholar
• Averell CM, Stanford RH, Laliberté F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58(1):102–111. doi:10.1080/02770903.2019.1663429.
   PubMed Web of Science ®Google Scholar
• Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, Kabra SK, Mohammed S, Sukumaran TU, Ghoshal AG, et al. Prevalence, time trends and treatment practices of asthma in India: the Global Asthma Network study. ERJ Open Res. 2022;8(2):00528–2021. doi:10.1183/23120541.00528-2021.
   PubMedGoogle Scholar
• GBD compare, Viz hub. 2021. Available from: https://vizhub.healthdata.org/gbdcompare/ [last accessed 25 March 2023].
   Google Scholar
• Salvi SS, Apte KK, Dhar R, Shetty P, Faruqi RA, Thompson PJ, Guleria R. Asthma insights and management in India: lessons learnt from the Asia Pacific - Asthma Insights and Management (AP-AIM) Study. J Assoc Physicians India. 2015;63(9):36–43. 27608865
   PubMedGoogle Scholar
• Global Initiative for Asthma. GINA Global Strategy for Asthma Management and Prevention, 2023. Updated May 2023. Available from: https://ginasthma.org.
   Google Scholar
• Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10(1):1. Cited: in:: PMID: 20051135. doi:10.1186/1471-2466-10-1.
   PubMedGoogle Scholar
• Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real world effects of once vs. greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111(3):216–220. Cited: in:: PMID: 23987199. doi:10.1016/j.anai.2013.06.008.
   PubMed Web of Science ®Google Scholar
• de Llano LP, Sanmartin AP, González-Barcala FJ, Mosteiro-Añón M, Abelaira DC, Quintas RD, Ventosa MM. Assessing adherence to inhaled medication in asthma: impact of once-daily versus twice-daily dosing frequency. The ATAUD study. J Asthma. 2018;55(9):933–938. Cited: in:: PMID: 29461875. doi:10.1080/02770903.2018.1426769.
   PubMed Web of Science ®Google Scholar
• Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37(2):204–211. doi:10.1111/j.1365-2710.2011.01285.x.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. The Lancet. 2017;390(10109):2247–2255. doi:10.1016/S0140-6736(17)32397-8.
   PubMed Web of Science ®Google Scholar
• Crompton GK. Dry powder inhalers: advantages and limitations. J Aerosol Med. 1991;4(3):151–156. doi:10.1089/jam.1991.4.151.
   PubMedGoogle Scholar
• Cataldo D, Hanon S, Peché RV, Schuermans DJ, Degryse JM, De Wulf IA, Elinck K, Leys MH, Rummens PL, Derom E. How to choose the right inhaler using a patient-centric approach? Adv Ther. 2022;39(3):1149–1163. Cited: in:: PMID: 35080761. doi:10.1007/s12325-021-02034-9.
   PubMed Web of Science ®Google Scholar
• Raphael G, Yiu G, Sakov A, Liu S, Caracta C. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older. J Asthma. 2018;55(6):640–650. doi:10.1080/02770903.2017.1350971.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Agarwal R, Dhooria S, Prasad KT, Sehgal I, Muthu V, Singh N, Behera D, Jindal SK, Singh V, et al. Joint Indian Chest Society-National College of Chest Physicians (India) guidelines for spirometry. Lung India. 2019;36(Supplement):S1–S35. doi:10.4103/lungindia.lungindia_300_18.
   PubMedGoogle Scholar
• Tepper RS, Wise RS, Covar R, Irvin CG, Kercsmar CM, Kraft M, Liu MC, O’Connor GT, Peters SP, Sorkness R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 Suppl):S65–S87. doi:10.1016/j.jaci.2011.12.986.
   PubMed Web of Science ®Google Scholar
• Tomlinson R, Parks D, Martin A. Comparative meta-analysis of the efficacy of once-daily fluticasone furoate 100 µG versus twice-daily fluticasone propionate 250 µG in adolescents and adults with persistent asthma. Lung. 2017;195(5):571–574. doi:10.1007/s00408-017-0041-2.
   PubMed Web of Science ®Google Scholar
• Furuhashi K, Fujisawa T, Hashimoto D, Kamiya Y, Yasui H, Karayama M, Suzuki Y, Hozumi H, Enomoto N, Nakamura Y, et al. Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial. J Asthma Allergy. 2019;12:253–261. doi:10.2147/JAA.S223093.
   PubMed Web of Science ®Google Scholar
• Svedsater H, Stynes G, Wex J, Frith L, Leather D, Castelnuovo E, Detry M, Berry S. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy. Asthma Res Pract. 2016;2(1):4. Cited: in:: PMID: 27965772. doi:10.1186/s40733-015-0016-0.
   PubMedGoogle Scholar
• Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MCJM, Verhamme KMC. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396–407. Cited: in:: PMID: 25323234. doi:10.1183/09031936.00075614.
   PubMed Web of Science ®Google Scholar
• Makhinova T, Barner JC, Richards KM, Rascati KL. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among Texas medicaid patients with persistent asthma. J Manag Care Spec Pharm. 2015;21(12):1124–1132. Cited: in:: PMID: 26679962. doi:10.18553/jmcp.2015.21.12.1124.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Shiobara T, Arai R, Chibana K, Takemasa A. Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study). J Thorac Dis. 2020;12(5):1877–1883. doi:10.21037/jtd-19-3913.
   PubMed Web of Science ®Google Scholar
• Averell CM, Laliberté F, Germain G, Duh MS, Lima R, Mahendran M, Slade DJ. Symptom control in patients with asthma using inhaled corticosteroids/long-acting β 2 -agonists (fluticasone furoate/vilanterol or budesonide/formoterol) in the US: a retrospective matched cohort study. J Asthma. 2022;59(9):1805–1818. doi:10.1080/02770903.2021.1963767.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–223. doi:10.1016/S2213-2600(13)70040-7.
   PubMed Web of Science ®Google Scholar
• Suggett J, Kushnarev V, Sadafi H. Dry Powder Inhalers (DPIs) vs Metered Dose Inhaler (MDI) with valved spacer: using Functional Respiratory Imaging (FRI) to assess modelled lung deposition in a COPD patient. 0501 - Airw Pharmacol Treat. Lausanne, Switzerland: European Respiratory Society. 2022:708. doi:10.1183/13993003.congress-2022.708.
   Google Scholar